Financial PerformancePfizer raised its full-year 2024 EPS guidance by 12% and revenue guidance by 3%, indicating strong financial performance and potential growth.
LeadershipChris Boshoff will become the new Chief Scientific Officer at Pfizer, bringing a wealth of experience and a successful track record in delivering innovative medicines.
Oncology PipelineA budding oncology pipeline with important trials and new studies initiated highlights potential for future growth at Pfizer.